Core Viewpoint - The core logic of the company is defined as focusing on product implementation and patient benefits rather than mere concepts [1] Group 1: Company Achievements and Innovations - The company made a significant debut at the China International Import Expo, showcasing three major achievements: the launch of the first domestic dual-chamber lyophilized preparation production line in collaboration with Dongfulong, the selection of Parathyroid hormone as a "good product" at the expo, and the imminent approval of Longpei growth hormone [1][2] - The dual-chamber lyophilized preparation technology is seen as a key solution to the industrialization bottleneck in high-end biopharmaceuticals, enhancing patient compliance [3][4] - The company aims to leverage the expo platform to connect with global innovation resources and attract more overseas technologies and products, enriching its endocrine disease product pipeline [2] Group 2: Market Potential and Product Development - Parathyroid hormone is positioned as a groundbreaking treatment for patients with parathyroid hormone deficiency, with the potential to become the first and only hormone replacement therapy for this condition globally [5] - The company has received approvals from major regulatory bodies, including the EMA, MHRA, and FDA, and plans to launch the product in China by September 2025 [5] - Longpei growth hormone is designed with a focus on "technological innovation" and "patient-friendly" features, adhering to high production standards to build trust among families [6][7] Group 3: Strategic Collaborations and Future Plans - The collaboration with Dongfulong is not only about technology implementation but also enhances the company's ability to control key production processes and establish a local commercial production layout [4] - The company is adopting a "dual-track" model for market entry, initially importing products to meet demand before launching domestically produced versions by 2028 [8] - The company is focused on building a collaborative ecosystem with high-end equipment manufacturers, CDMO partners, and specialized channels to ensure efficient product development and commercialization [11][12] Group 4: Growth Strategy and Market Trends - The company's growth strategy emphasizes deepening its focus on the endocrine field, targeting clinically urgent needs and leveraging local technological innovations to create competitive advantages [14] - The Chinese growth hormone market is expected to transition to long-acting products, with long-acting therapies projected to capture 90% of the market share in a market valued at billions [15] - The company aims to provide high-quality treatment options for patients, ensuring that innovative drugs are developed to meet global standards [15]

Core Insights - Weisheng Pharmaceutical made its debut as an exhibitor at the 8th China International Import Expo, showcasing two global innovative drugs: the "world's first" drug Parathyroid Hormone (PTH) and the "potential best-in-class" drug Long-acting Growth Hormone [1][2] Group 1: Product Innovations - Parathyroid Hormone (PTH) is the first and only hormone replacement therapy for adult chronic hypoparathyroidism (HP), filling a long-standing gap in China's treatment options and breaking decades-long treatment deadlock [2] - PTH has received marketing approvals from the European Medicines Agency (EMA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and the US Food and Drug Administration (FDA) [2] - The application for Long-acting Growth Hormone is under review by the National Medical Products Administration of China, with approval expected in 2025, potentially providing a new treatment option for children with growth hormone deficiency [2] Group 2: Strategic Collaborations - Weisheng Pharmaceutical signed a strategic cooperation agreement with Dongfulong Technology Group, focusing on the development and application of dual-chamber lyophilized formulation technology [3] - This technology allows for the physical separation of the drug and diluent in a closed container, simplifying the preparation process for injections [3] - The collaboration aims to fill a technological gap in China's high-end biopharmaceutical sector and provide advanced drug delivery solutions [3] Group 3: Commitment to Market - Weisheng Pharmaceutical is committed to accelerating the industrialization of its global first products, including Long-acting Growth Hormone and Parathyroid Hormone, to enhance endocrine treatment levels in China [3] - The company aims to ensure that more patients benefit from innovative medical advancements rooted in global research and development [3]